Within our focus of providing services in antibody discovery and engineering, Abzyme is pursuing additional select, strategic partnerships, to further leverage our powerful Triple-mode Antibody Discovery platform with proprietary antibody libraries and Abz2 Bispecifics Technology. Through the Triple-mode Antibody Discovery platform that mimics mammalian antibody diversification & affinity maturation processes, each discovery/optimization cycle finishes within weeks from target to antibodies of various formats with desired attributes. Through the “plug-and-play” process, an existing IgG traditional antibody can be rapidly transformed into well-expressing Abz2 bispecifics with a completely normal IgG structure. This creates a multitude of opportunities for developing novel biologics with improved therapeutic indices.
Five proprietary yeast-based antibody libraries (human IgG, human ScFV, human VH, camelid VHH and rabbit IgG) on the Triple-mode Antibody Discovery platform have been established to serve the needs of academic institutions and biopharmaceutical companies. These technology-centric assets are available in a variety of business arrangements including contract service, licensing and partnerships.
Abz2 Bispecifics Technology enables the conversion of existing traditional antibodies into well-expressing bispecifics. Abz2 TfR Bispecifics Technology is available for licensing to develop antibodies capable to overcome the blood-brain barrier. Abz2 CD3 Bispecifics Technology is available for licensing to develop T-cell engaging bispecific antibodies for oncology and immuno-oncology targets. In addition, Abzyme is open to partnership in developing customized antibodies and Abz2 bispecifics to serve your needs.